Natera, Inc. leverages its proprietary cell-free DNA (cfDNA) molecular diagnostics platform across oncology, women’s health, and organ health to drive robust revenue gains, with product revenues exceeding $2.29 billion in 2025. Despite this growth trajectory, the company continues to post substantial operating losses, though it has notably improved operating cash flow and free cash flow generation recently. Key growth drivers include Signatera’s personalized circulating tumor DNA test for oncology, Panorama’s leading non-invasive prenatal testing, and innovative transplant rejection assays. Natera’s extensive patent portfolio and FDA Breakthrough Device Designations underpin its competitive moat but regulatory and reimbursement risks remain material challenges.